A Phase 2 interventional study of TEV-48574 and Placebo in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Terminated at 97 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-13.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. — none open to participants now, 1 under way, 1 of them phase 3. Asthma · Teva Pharmaceutical Industries, Ltd..
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., this one is the 38th largest by enrollment of the 51 interventional ones that give a count, is one of 2 that started in 2020, is one of 11 in phase 2, and was the 49th registered.
4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.
Browse Asthma studies →None of the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd. is open now. The open studies under Asthma, anywhere →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 65 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 317 across the 51 interventional studies, 1,025 across the 2 observational. Of the 52 that completed or were terminated, 36 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Teva Branded Pharmaceutical Products R&D, Inc., one of the names counted as Teva Pharmaceutical Industries, Ltd.. Under that name alone:
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
1 of the studies in Asthma by Teva Pharmaceutical Industries, Ltd. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06052267Phase 3Teva Branded Pharmaceutical Products R&D LLCA Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies in Asthma by Teva Pharmaceutical Industries, Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the effect of TEV-48574 compared with placebo on loss of asthma control (LoAC) in adult participants with T2-low and non-T2 severe asthma uncontrolled on inhaled corticosteroids plus long-acting beta-agonists (ICS+LABA).
The secondary efficacy objective is to evaluate the effect of TEV-48574 compared with placebo on a range of clinical measures of asthma control.
The duration of participant participation in the study is planned to be up to approximately 30 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NOTE- Additional criteria apply, please contact the investigator for more information
Exclusion Criteria:
NOTE- Additional criteria apply, please contact the investigator for more information
Participants will receive the investigational medicinal product (IMP) loading doses on the day of randomization and the subsequent corresponding IMP maintenance doses every 2 weeks for a total of 8 doses (1 loading dose and 7 maintenance doses).
Drug: TEV-48574
Participants will receive placebo matching to TEV-48574 SC every 2 weeks for a total of 8 doses.
Drug: Placebo
subcutaneous infusion
Matching Placebo
Number of Participants Who Experienced Loss of Asthma Control (LoAC) During the Treatment Period
The LoAC was defined as any 1 of the following during the treatment period: - morning peak expiratory flow (PEF) decrease ≥30% from baseline on 2 consecutive days or morning handheld forced expiratory volume in the first second of exhalation (FEV1) decrease ≥20% from baseline on 2 consecutive days; - increase in short-acting beta-agonist (SABA)/quick-relief medication ≥6 puffs over baseline use in 24 hours on 2 consecutive days; increase in inhaled corticosteroids (ICS) dose ≥4 × most recent dose; - systemic corticosteroid use; - asthma emergency room (ER) visit or hospitalization.
Time frame: From randomization (Week 0) until Week 16
Time From Randomization to LoAC During the Treatment Period
Time (in days) from randomization to LoAC during the treatment period is the interval from randomization to the occurrence of the LoAC. The LoAC was defined as any 1 of the following during the treatment period: - morning PEF decrease ≥30% from baseline on 2 consecutive days or morning handheld FEV1 decrease ≥20% from baseline on 2 consecutive days; - increase in SABA/quick-relief medication ≥6 puffs over baseline use in 24 hours on 2 consecutive days; increase in ICS dose ≥4 × most recent dose; - systemic corticosteroid use; - asthma ER visit or hospitalization.
Time frame: From randomization (Week 0) until Week 16
Change From Baseline in Asthma Control Questionnaire 6-Question Version (ACQ-6) Score at Week 16
The ACQ-6 is a 6-item validated asthma assessment tool that has been widely used. Six questions are self-assessments (completed by the participant), 5 questions assessing asthma symptoms: night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and 1 question for short-acting bronchodilator use. Each item on the ACQ-6 has a possible score ranges from 0 to 6, and the total score is the mean of all responses. The total score ranging from 0-6 (0=totally controlled and 6=severely uncontrolled). A higher score indicated poorer asthma control.
Time frame: Baseline, Week 16
Change From Baseline in Percent Predicted Forced Expiratory Volume in the First Second (FEV1) at Week 16
FEV1 (measured by handheld spirometer) is the volume of air that can be forcibly exhaled from the lungs in the first second. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%.
Time frame: Baseline, Week 16
Change From Baseline in Daily Average Use of Short-acting Beta-agonist (SABA) Quick Relief Medication at Week 16
Number of inhalations/puffs of SABA/quick relief inhaler used was recorded in the e-diary daily.
Time frame: Baseline, Week 16
Number of Participants Who Had a Clinical Asthma Exacerbation (CAE) During the Treatment Period
The CAEs during the study were defined as a worsening of asthma symptoms resulting in any 1 of the following: - the use of systemic corticosteroids (oral or injectable); - an emergency department visit due to asthma treated with systemic corticosteroids; - an inpatient hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the e-diary/handheld spirometer).
Time frame: From randomization (Week 0) until Week 16
Time From Randomization to First CAE During the Treatment Period for Participants With CAE
The CAEs during the study were defined as a worsening of asthma symptoms resulting in any 1 of the following: - the use of systemic corticosteroids (oral or injectable); - an emergency department visit due to asthma treated with systemic corticosteroids; - an inpatient hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the e-diary/handheld spirometer).
Time frame: From randomization (Week 0) until Week 16
Change From Baseline in Number of Nighttime Awakenings Due to Asthma at Week 16
Participants recorded the number of nighttime awakenings due to asthma in the e-diary daily, in the morning.
Time frame: Baseline, Week 16
Percent Change in ICS Dose During the Treatment Period
The ICS dose was not collected in the participant diary as planned.
Time frame: From randomization (Week 0) until Week 16
Change From Baseline in Forced Vital Capacity (FVC) at Week 16
FVC (measured by handheld spirometer) is the volume of air that can be forcibly and completely blown out after full inspiration, measured in liters.
Time frame: Baseline, Week 16
Change From Baseline in Forced Expiratory Flow at 25-75% of Pulmonary Volume (FEF25%-75%) at Week 16
The FEF25%-75% (measured by handheld spirometer) is the forced expiratory flow from 25% to 75% of FVC
Time frame: Baseline, Week 16
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 16
FeNO was performed prior to the on-site spirometry.
Time frame: Baseline, Week 16
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Serious adverse events (SAEs) included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered treatment emergent (TEAEs) if onset occurred on or after the first dose date. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. AEs include clinically significant changes from baseline in any one of the following categories: clinical laboratory test results, vital signs, ECG findings.
Time frame: From randomization (Week 0) until Week 24
| Milestone | Placebo | TEV-48574 |
|---|---|---|
| Started | 32 | 33 |
| Received at least 1 dose of study drug | 31 | 33 |
| Completed | 17 | 20 |
| Not completed | 15 | 13 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Loss of asthma control (loac) | 0 | 1 |
| Withdrew: Study termination | 10 | 10 |
| Withdrew: Sponsor decision | 2 | 2 |
| Withdrew: Other than specified | 1 | 0 |
The LoAC was defined as any 1 of the following during the treatment period: - morning peak expiratory flow (PEF) decrease ≥30% from baseline on 2 consecutive days or morning handheld forced expiratory volume in the first second of exhalation (FEV1) decrease ≥20% from baseline on 2 consecutive days; - increase in short-acting beta-agonist (SABA)/quick-relief medication ≥6 puffs over baseline use in 24 hours on 2 consecutive days; increase in inhaled corticosteroids (ICS) dose ≥4 × most recent dose; - systemic corticosteroid use; - asthma emergency room (ER) visit or hospitalization.
| Participants | Placebo | TEV-48574 |
|---|---|---|
| Number of Participants Who Experienced Loss of Asthma Control (LoAC) During the Treatment Period | 13 | 17 |
Time (in days) from randomization to LoAC during the treatment period is the interval from randomization to the occurrence of the LoAC. The LoAC was defined as any 1 of the following during the treatment period: - morning PEF decrease ≥30% from baseline on 2 consecutive days or morning handheld FEV1 decrease ≥20% from baseline on 2 consecutive days; - increase in SABA/quick-relief medication ≥6 puffs over baseline use in 24 hours on 2 consecutive days; increase in ICS dose ≥4 × most recent dose; - systemic corticosteroid use; - asthma ER visit or hospitalization.
| days | Placebo | TEV-48574 |
|---|---|---|
| Time From Randomization to LoAC During the Treatment Period | NA (60.0 to NA) | 109.0 (45.0 to NA) |
The ACQ-6 is a 6-item validated asthma assessment tool that has been widely used. Six questions are self-assessments (completed by the participant), 5 questions assessing asthma symptoms: night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing, and 1 question for short-acting bronchodilator use. Each item on the ACQ-6 has a possible score ranges from 0 to 6, and the total score is the mean of all responses. The total score ranging from 0-6 (0=totally controlled and 6=severely uncontrolled). A higher score indicated poorer asthma control.
| units on a scale | Placebo | TEV-48574 |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire 6-Question Version (ACQ-6) Score at Week 16 | -0.560 ± 0.4546 | -0.833 ± 0.7250 |
FEV1 (measured by handheld spirometer) is the volume of air that can be forcibly exhaled from the lungs in the first second. The percent predicted FEV1 equals the participant's observed FEV1 divided by the participant's predicted FEV1 (determined by height and race) and converted to a percentage by multiplying by 100%.
| %predicted FEV1 | Placebo | TEV-48574 |
|---|---|---|
| Change From Baseline in Percent Predicted Forced Expiratory Volume in the First Second (FEV1) at Week 16 | 0.121 ± 8.3126 | 4.844 ± 12.4343 |
Number of inhalations/puffs of SABA/quick relief inhaler used was recorded in the e-diary daily.
| puffs of SABA/day | Placebo | TEV-48574 |
|---|---|---|
| Change From Baseline in Daily Average Use of Short-acting Beta-agonist (SABA) Quick Relief Medication at Week 16 | -0.235 ± 1.2641 | -0.305 ± 1.6501 |
The CAEs during the study were defined as a worsening of asthma symptoms resulting in any 1 of the following: - the use of systemic corticosteroids (oral or injectable); - an emergency department visit due to asthma treated with systemic corticosteroids; - an inpatient hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the e-diary/handheld spirometer).
| Participants | Placebo | TEV-48574 |
|---|---|---|
| Number of Participants Who Had a Clinical Asthma Exacerbation (CAE) During the Treatment Period | 2 | 3 |
The CAEs during the study were defined as a worsening of asthma symptoms resulting in any 1 of the following: - the use of systemic corticosteroids (oral or injectable); - an emergency department visit due to asthma treated with systemic corticosteroids; - an inpatient hospitalization due to asthma. Worsening asthma included new or increased symptoms or signs that either worried the participant or were related to an asthma-specific alert (if available through the e-diary/handheld spirometer).
| days | Placebo | TEV-48574 |
|---|---|---|
| Time From Randomization to First CAE During the Treatment Period for Participants With CAE | 46.5 (38 to 55) | 37.0 (30 to 54) |
Participants recorded the number of nighttime awakenings due to asthma in the e-diary daily, in the morning.
| nighttime awakenings | Placebo | TEV-48574 |
|---|---|---|
| Change From Baseline in Number of Nighttime Awakenings Due to Asthma at Week 16 | -1.224 ± 2.0182 | -0.208 ± 2.7274 |
The ICS dose was not collected in the participant diary as planned.
No measurements were reported for this outcome.
FVC (measured by handheld spirometer) is the volume of air that can be forcibly and completely blown out after full inspiration, measured in liters.
| liters | Placebo | TEV-48574 |
|---|---|---|
| Change From Baseline in Forced Vital Capacity (FVC) at Week 16 | 0.014 ± 0.3052 | 0.155 ± 0.3964 |
The FEF25%-75% (measured by handheld spirometer) is the forced expiratory flow from 25% to 75% of FVC
| liters/second | Placebo | TEV-48574 |
|---|---|---|
| Change From Baseline in Forced Expiratory Flow at 25-75% of Pulmonary Volume (FEF25%-75%) at Week 16 | -0.026 ± 0.2451 | 0.166 ± 0.4342 |
FeNO was performed prior to the on-site spirometry.
| parts per billion (ppb) | Placebo | TEV-48574 |
|---|---|---|
| Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 16 | 5.364 ± 6.9609 | 10.375 ± 12.5850 |
An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Serious adverse events (SAEs) included death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered treatment emergent (TEAEs) if onset occurred on or after the first dose date. A summary of serious and non-serious AEs regardless of causality is located in 'Reported Adverse Events module'. AEs include clinically significant changes from baseline in any one of the following categories: clinical laboratory test results, vital signs, ECG findings.
| Participants | Placebo | TEV-48574 |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 14 | 18 |
Collected over From randomization (Week 0) until Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/31 (0%) | 1/31 (3.2%) | 4/31 (12.9%) |
| TEV-48574 | 0/33 (0%) | 1/33 (3%) | 6/33 (18.2%) |
| Event | Placebo | TEV-48574 |
|---|---|---|
| Vaginal prolapseReproductive system and breast disorders | 1/31 | 0/33 |
| Hypertensive crisisVascular disorders | 0/31 | 1/33 |
| Event | Placebo | TEV-48574 |
|---|---|---|
| NasopharyngitisInfections and infestations | 3/31 | 3/33 |
| HeadacheNervous system disorders | 2/31 | 3/33 |
The intent-to-treat (ITT) analysis set included all randomized participants.
| Age, Continuous(years) | Placebo | TEV-48574 | Total |
|---|---|---|---|
| Mean | 56.3 ± 14.14 | 58.8 ± 12.38 | 57.6 ± 13.23 |
| Sex: Female, Male(Participants) | Placebo | TEV-48574 | Total |
|---|---|---|---|
| Female | 19 | 22 | 41 |
| Male | 13 | 11 | 24 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | TEV-48574 | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 6 | 11 |
| Not Hispanic or Latino | 27 | 27 | 54 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo | TEV-48574 | Total |
|---|---|---|---|
| Race — White | 28 | 26 | 54 |
| Race — Black or African American | 4 | 6 | 10 |
| Race — Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.)
Ran from Oct 2020 to primary completion in Jan 2022, 15 months.
Results were first posted in Mar 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Duvakitug
Teva Branded Pharmaceutical Products R&D, Inc. →